Anesthetic

Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18

Retrieved on: 
Monday, January 16, 2023
Medical Supplies, Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, FRANZCR, Cell, MS, Auckland City Hospital, Aortoiliac occlusive disease, Safety, SCB Park Plaza, ISET, PHD, ONZM, Master of Medicine, Sale, DCB, Restenosis, International Symposium on Endovascular Therapy, Pharmaceutical industry, FRACS, Bachelor of Medicine, Bachelor of Surgery, MBBS, Anesthetic

The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida.

Key Points: 
  • The session will be held on Wednesday, January 18, at the 35th annual International Symposium on Endovascular Therapy (ISET) conference in Miami, Florida.
  • Professor Varcoe will also discuss the differentiated capabilities of the Surmodics crystalline drug release platform for sirolimus-coated balloons (SCBs) in connection with 12-month data from the SWING trial.
  • Professor Varcoe recently presented SWING Trial 12-month data on Nov. 16 at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium).
  • The Sundance Sirolimus Drug-Coated Balloon is not available for sale anywhere in the world, and currently is for investigational use only.

Animal Protection Party of Canada Investigation reveals piglets poisoned, irradiated, mutilated and killed for military medical training

Retrieved on: 
Friday, January 6, 2023
Uniformed Services University of the Health Sciences, Advanced trauma life support, National security, Anesthesia, Defense, Record, Toronto, AAC, Skin, Toronto Star, Trauma, Risk, Animal, DND, Face, Animal testing, Seizure, Anesthetic, U.S. Coast Guard environmental protection, APPC, Anesthesiology, Walls (Louis Tomlinson album), Animal Protection Party of Canada, Hospital, Pig, Access

TORONTO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- A new Animal Protection Party of Canada (APPC) investigation exposes the cruel, unethical and dangerous use of piglets for "live tissue training" by the Department of National Defence (DND).

Key Points: 
  • TORONTO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- A new Animal Protection Party of Canada (APPC) investigation exposes the cruel, unethical and dangerous use of piglets for "live tissue training" by the Department of National Defence (DND).
  • This report provides the most detailed insight to date into the DND's use of animals for military medical training.
  • And yet, between 2012 and 2016 the DND squandered approximately $700,000 in tax-payer funds by purchasing approximately 700 piglets* for cruel, obsolete and inapplicable training.
  • Over 70% of NATO members no longer use animals for military medical training.

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF

Retrieved on: 
Monday, January 2, 2023
Aspirin, PAIN, CMS, Human, Patient, Elective surgery, Tears, Vomiting, SAN, Boxed warning, Drug discovery, Media contacts database, Liver, Head, Ibuprofen, Meloxicam, Headache, Media, Shanda, Ulcer, Allergy, Anemia, Stroke, Risk, Medicine, Medicare, Pharming, FDA, Safety, Cartilage, Degenerative disease, Death, News, Abdominoplasty, Foot, Ankle, Anesthetic, Constipation, Time-invariant system, Heron, Heart failure, Pain, Congress, Legislation, Nonsteroidal anti-inflammatory drug, Naproxen, Centers for Medicare & Medicaid Services, Gastrointestinal bleeding, New Drug Application, Bupivacaine, Pregnancy, Health insurance, Pharmaceutical industry, Frankincense

SAN DIEGO, Dec. 29, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced the submission of a supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to support the proposed indication for greatly expanded use of ZYNRELEF in soft tissue and orthopedic surgical procedures and a newly passed congressional bill that is anticipated to provide separate reimbursement outside of the packaged surgical payment for ZYNRELEF for almost 3 years.

Key Points: 
  • 2617, the omnibus spending bill approved by Congress last week includes a provision (SEC.
  • In two Phase 3 trials, ZYNRELEF demonstrated the ability to significantly increase the proportion of patients taking no opioids after surgery and we believe it qualifies for this separate payment.
  • ZYNRELEF currently has pass-through status in the outpatient setting of care through March 31, 2025 and this provision should extend separate reimbursement outside of the packaged surgical payment through December 31, 2027.
  • Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.

Insights on the Central Nervous System Therapeutic Global Market to 2027 - Ongoing Collaborations Among Manufacturers to Increase Drug Efficiency Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022
Managed Care, Pharmaceutical, Health, Neurology, Ansoff Matrix, Observation, Central nervous system, SWOT, Competitive analysis, Degenerative disease, Emotion, COVID-19, Investment, Growth, Porter's five forces analysis, Mental health, Impact, USD, Market development, Risk, Pharmaceutical industry, Retail, Risk management, Medical device, Trauma, Disease, Geography, Anesthetic, Analgesic, Cancer

Market dynamics are forces that impact the prices and behaviors of the Global Central Nervous System Therapeutic Market stakeholders.

Key Points: 
  • Market dynamics are forces that impact the prices and behaviors of the Global Central Nervous System Therapeutic Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Central Nervous System Therapeutic Market.
  • The report offers a comprehensive evaluation of the Global Central Nervous System Therapeutic Market.
  • The Global Central Nervous System Therapeutic Market is segmented based on Disease, Drug Class, and Geography.

Rock Band CORE Taps New Lead Singer & Front Man Mark Morales

Retrieved on: 
Thursday, December 8, 2022
Social media, Gemini Syndrome, Bad Boy, Rio Grande, Interview, JASON, CORE, BAD, Anesthetic, Human, TKO, FIVE, Bill, Lion, Sea shanty, Death, Frying pan, LINKIN PARK, Record, VAMPS, Sons of Texas, Music, Nightclub

LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- The four-time Billboard charting national recording act, the rock band CORE has brought in a new lead singer replacement.

Key Points: 
  • LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- The four-time Billboard charting national recording act, the rock band CORE has brought in a new lead singer replacement.
  • The former front man for the lone star rock outfit, SONS OF TEXAS, MARK MORALES has been tapped to head CORE.
  • Replacing the exiting CORE former lead vocalist, CJ Bills, who the label says, parted ways mutually with the band earlier this year as Bills pursues a different musical direction.
  • Quinn says "I always wanted Mark Morales for a music project, and I knew CORE would be the right band fit for him."

Global Inhalation Anesthetics Market to Reach $1.5 Billion by 2027 at a CAGR of 3.7% - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Medical Devices, Hospitals, Health, Health Technology, Medical Supplies, Desflurane, Growth, Sevoflurane, Anesthesia, Anesthetic, Inhalation, COVID-19, Video game

In the changed post COVID-19 business landscape, the global market for Inhalation Anesthetics estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 3.7% over the analysis period 2020-2027.

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Inhalation Anesthetics estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 3.7% over the analysis period 2020-2027.
  • Sevoflurane, one of the segments analyzed in the report, is projected to record a 3.6% CAGR and reach US$906.9 Million by the end of the analysis period.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$273.6 Million by the year 2027 trailing a CAGR of 3.4% over the analysis period 2020 to 2027.
  • In the global Nitrous Oxide segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment.

US Anesthesia Drugs and Devices Market Report 2022: Growing Healthcare Expenditure Fueling Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Hospitals, Pharmaceutical, Health, Surgery, Anesthetic, Device, ASC, Lidocaine, Ageing, Quality of life, TIVA, Pain, Acceleration, Growth, COVID-19, Inhalation, Benzocaine, Bupivacaine, Patient, Incidence, Dentistry, Medical device, Ropivacaine, Prilocaine, Anesthesia

The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion.

Key Points: 
  • The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion.
  • By Segment: The report provides the bifurcation of the market into two categories based on the segment: anesthesia drugs and anesthesia devices.
  • By Type: On the basis of type, the US anesthesia drugs market is divided into three types namely general, local and other anesthesia.
  • Growth Drivers: One of the most important factors impacting the US anesthesia drugs and devices market is rising geriatric population.

Piramal Critical Care (PCC) commits to reduce its environmental footprint and growing responsibly through sustainable operations

Retrieved on: 
Thursday, November 17, 2022
The Carlyle Group, Myxedema coma, Environment, LED, PPS, Spasticity, Steam, Plasma, Climate change, Coal, Hazardous waste, Allergan, Tree, US FDA, ESG, Absorption, Anesthetic, Organization, Carbon, NSE, Anesthesia, McNeil Consumer Healthcare, Sustainability, Social, Recycling, Waste management, Policy, Pain management, Ophthalmology, Electricity, PCC, Critical care, Inhalation, PPL, Sustainability reporting, UK, GHG, Fine chemical, Renewable energy, Management

MUMBAI, India, Nov. 17, 2022 /PRNewswire/ -- Piramal Critical Care (PCC) has integrated its sustainability framework with its strategy as well as daily business practices. As part of the endeavour, PCC's Environment, Social and Governance (ESG) policy covers sustainable and environment-friendly practices across energy and waste management, climate change management, greenhouse gas (GHG) reduction, water stewardship, supplier assessment, and integration of sustainability into our operations to ensure continual improvement in our performance and employee engagement. PCC is the complex hospital generics business under Piramal Pharma Limited (PPL). PCC's commitment towards sustainability dovetails into the overall objective of integrating sustainable practices across all businesses under PPL, as articulated in PPL's Sustainability Report FY 21–22.

Key Points: 
  • Under the ESG strategy, one of the key focus areas for Piramal is sustainability initiatives.
  • Energy management is one of our primary focus areas because of its direct influence on emissions and costs associated with our operations.
  • Piramal Critical Care (PCC) is a global leader in anesthesia, pain management, and intrathecal therapy.
  • PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.

Piramal Critical Care (PCC) commits to reduce its environmental footprint and growing responsibly through sustainable operations

Retrieved on: 
Thursday, November 17, 2022
The Carlyle Group, Myxedema coma, Environment, LED, PPS, Spasticity, Steam, Plasma, Climate change, Coal, Hazardous waste, Allergan, Tree, US FDA, ESG, Absorption, Anesthetic, Organization, Carbon, NSE, Anesthesia, McNeil Consumer Healthcare, Sustainability, Social, Recycling, Waste management, Policy, Pain management, Ophthalmology, Electricity, PCC, Critical care, Inhalation, PPL, Sustainability reporting, UK, GHG, Fine chemical, Renewable energy, Management

MUMBAI, India, Nov. 17, 2022 /PRNewswire/ -- Piramal Critical Care (PCC) has integrated its sustainability framework with its strategy as well as daily business practices. As part of the endeavour, PCC's Environment, Social and Governance (ESG) policy covers sustainable and environment-friendly practices across energy and waste management, climate change management, greenhouse gas (GHG) reduction, water stewardship, supplier assessment, and integration of sustainability into our operations to ensure continual improvement in our performance and employee engagement. PCC is the complex hospital generics business under Piramal Pharma Limited (PPL). PCC's commitment towards sustainability dovetails into the overall objective of integrating sustainable practices across all businesses under PPL, as articulated in PPL's Sustainability Report FY 21–22.

Key Points: 
  • Under the ESG strategy, one of the key focus areas for Piramal is sustainability initiatives.
  • Energy management is one of our primary focus areas because of its direct influence on emissions and costs associated with our operations.
  • Piramal Critical Care (PCC) is a global leader in anesthesia, pain management, and intrathecal therapy.
  • PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.

Dental Anesthesia Market to be Worth $2.81 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Tuesday, November 15, 2022
SAN, Growth, Revenue, Pain, General officer, Dentist, Population, National Institute, Local, Awareness, Anesthetic, Dentistry, CAGR, Ageing, Radioactive decay, CDC, Patient, COVID-19, USD, Lidocaine, Mouth, Brain, Hospital, Tooth decay, Prevalence

Key Industry Insights & Findings from the report:

Key Points: 
  • Key Industry Insights & Findings from the report:
    The local segment dominated the dental anesthesia market with a market share of 52.9% in 2022.
  • Read 100 page full market research report, " Dental Anesthesia Market Size, Share & Trends Analysis Report By Type (Local, General, Sedation), By End Use (Hospitals, Dental Clinics, Others), By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • The rising demand for dental check-ups and the increased prevalence of dental problems are two factors that are primarily driving the growth of the dental anesthesia market.
  • Grand View Research has segmented the dental anesthesia market based on type, end-use, and region:
    Dental AnesthesiaMarket - Type Outlook (Revenue, USD Million, 2018 - 2030)